Sanofi-aventis
GUILDFORD, England, December 17, 2010 - Sanofi-aventis and Oxford University have entered into an
agreement to conduct multi-phase oncology clinical and translational research
with INDOX, India's leading academic oncology network.
PARIS, November 8, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has
sent a letter to Genzyme Corporation (Nasdaq: GENZ) requesting that Genzyme
clarify its position on a number of potential Board actions raised in
Genzyme's Schedule 14D-9.
PARIS, November 5, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
that it is a partner in a new multidisciplinary atrial fibrillation research
consortium, the "European Network for Translational research in Atrial
Fibrillation" (EUTRAF), which has been awarded a EUR12 million grant to
engage in atrial fibrillation (AF) research.
PARIS, October 26, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
the initiation of a multinational Phase III study evaluating the efficacy and
safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo
in patients with relapsing multiple sclerosis (RMS) treated with interferon
beta (IFN beta).
PARIS, October 15, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results
from the two year phase III TEMSO study of teriflunomide, a novel oral
disease modifier investigated for the treatment of relapsing multiple
sclerosis (RMS).
More News
- Phase III Study Results Also Demonstrated the Therapy had Acceptable Safety Profile
- Findings Presented at European Association for the Study of Diabetes (EASD) 46th Annual Meeting
- Over 10,000 Patients Included in RealiseAF
- First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010
- Multaq(R) First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation
- One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting
- For non-U.S. media only
- Sanofi-aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document
- First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years
- The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes
- Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
- Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
- FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
- Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
